The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A major new study has found that women over 55 are leading the way in weight loss –outperforming younger users of Wegovy and Mounjaro ... tracking their weight on average six times per month ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

The average ... to declare the weight-loss drug shortages over. The Outsourcing Facilities Association sued the FDA on Monday over its decision to declare Novo Nordisk's Wegovy and Ozempic are ...

which is over half of the likely global adult population at that time. With millions flocking to get access to weight-loss drugs, Goldman Sachs projected global sales from next-gen obesity drugs ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

The average weight loss among those taking the new drug was 15.7% after 68 weeks, compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...